Please assess the completion status of the following clinical trial:

Trial Title: A Multiple Dose Study Of PF-04950615 (RN316) In Subjects On Maximum Doses Of Statins

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index (BMI) of 18.5 to 40 kg/m2~* On a stable maximum daily dose of a statin, defined as atorvastatin 80 mg or rosuvastatin 40 mg for a minimum of 45 days prior to Day 1.~* Lipids meet the following criteria twice during screening period:~* Fasting LDL C = or \> 80 mg/dL;~* Fasting TG \< 400 mg/dL.~Exclusion Criteria:~* History of a cardiovascular or cerebrovascular event or procedure (eg, MI, stroke, TIA, angioplasty) during the past year.~* Poorly controlled type 1 or type 2 diabetes mellitus.~* Poorly controlled hypertension.~* Fasting triglycerides \> 400 mg/dL~* 12 lead ECG demonstrating QTcFF \>455 msec at screening.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment A (Type: PLACEBO_COMPARATOR): None
- Treatment B (Type: EXPERIMENTAL): None
- Treatment C (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).